Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amineptine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.97 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.97 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amineptine SCHEMBL340428 | 1.00 | HTR2C (0.97) | HTR2CSLC6A3NR1I2OPRM1DRD3 | |
| Amineptine SCHEMBL34086 | 0.99 | HTR2C (1.00) | HTR2CSLC6A3NR1I2OPRM1DRD3 | |
| Amineptine SCHEMBL5783484 | 0.99 | HTR2C (1.00) | HTR2CSLC6A3NR1I2OPRM1DRD3 | |
| Amineptine SCHEMBL29389410 | 0.99 | HTR2C (1.00) | HTR2CSLC6A3NR1I2OPRM1DRD3 | |
| SCHEMBL28969679 | 0.82 | HTR2C (0.72) | HTR2CSLC6A3NR1I2OPRM1DRD3 | |
| Amineptine SCHEMBL8700558 | 0.80 | HTR2C (0.66) | HTR2CSLC6A3NR1I2OPRM1DRD3 | |
| Amineptine SCHEMBL28280844 | 0.79 | SLC6A3 (0.65) | HTR2CSLC6A3NR1I2OPRM1DRD3 | |
| SCHEMBL9248431 | 0.77 | HTR2C (0.64) | HTR2CSLC6A3OPRM1SMPD1KMT2A | |
| SCHEMBL390761 | 0.74 | HTR2C (0.60) | HTR2CSLC6A3KMT2AALDH1A1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL19180243 | 0.74 | NR1I2 (0.78) | HTR2CSLC6A3NR1I2OPRM1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1273301-B1 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON SA (CH) | 2006-09-06 | — | — | EP | claimed |
| EP-1273301-A2 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON S.A. (CH) | 2003-01-08 | — | — | EP | claimed |
| EP-2806034-B1 | Compounds and uses thereof to induce an immunogenic cancer cell death in a subject | ROUSSY INST GUSTAVE (FR) | 2017-06-28 | — | — | EP | disclosed |
| EP-2806034-A1 | Compounds and uses thereof to induce an immunogenic cancer cell death in a subject | Institut Gustave Roussy (FR) | 2014-11-26 | — | — | EP | disclosed |
| US-8865653-B2 | Method of treatment for immunogenic treatment resistant cancer | INSTITUT GUSTAVE ROUSSY (FR) | 2014-10-21 | — | — | US | disclosed |
| US-8828944-B2 | Compounds and uses thereof to induce an immunogenic cancer cell death in a subject | INSTITUT GUSTAVE ROUSSY (FR) | 2014-09-09 | — | — | US | disclosed |
| US-20130156790-A1 | COMPOUNDS AND USES THEREOF TO INDUCE AN IMMUNOGENIC CANCER CELL DEATH IN A SUBJECT | INSTITUT GUSTAVE ROUSSY (FR) | 2013-06-20 | — | — | US | disclosed |
| US-20130052160-A1 | COMPOUNDS AND USES THEREOF TO INDUCE AN IMMUNOGENIC CANCER CELL DEATH IN A SUBJECT | INSTITUT GUSTAVE ROUSSY (FR) | 2013-02-28 | — | — | US | disclosed |
| EP-2561088-A1 | COMPOUNDS AND USES THEREOF TO INDUCE AN IMMUNOGENIC CANCER CELL DEATH IN A SUBJECT | Institut Gustave Roussy (FR) | 2013-02-27 | — | — | EP | disclosed |
| US-8231899-B2 | An orally-administered drug having low solubility in acid environment, e.g. stomach, being a powder contacted with water to form particules where >50% pass through sieve 180 mu m; in 0.07 N hydrochloric acid >50% released within 20 min.; high strength tablets; bioavailability; drug delivery | NYCOMED DANMARK APS (DK) | 2012-07-31 | — | — | US | disclosed |
| WO-2012007783-A1 | KITS AND METHODS FOR DETECTING THE ABILITY TO INDUCE AN IMMUNOGENIC CANCER CELL DEATH IN A SUBJECT | INSTITUT GUSTAVE ROUSSY (FR) | 2012-01-19 | — | — | WO | disclosed |
| EP-1109534-B1 | QUICK RELEASE PHARMACEUTICAL COMPOSITIONS OF DRUG SUBSTANCES | NYCOMED DANMARK AS (DK) | 2003-02-12 | — | — | EP | disclosed |
| EP-1273301-A2 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON S.A. (CH) | 2003-01-08 | — | — | EP | disclosed |
| EP-1109534-A1 | QUICK RELEASE PHARMACEUTICAL COMPOSITIONS OF DRUG SUBSTANCES | NYCOMED DANMARK A/S (DK) | 2001-06-27 | — | — | EP | disclosed |
| EP-1017370-A1 | MODIFIED RELEASE MULTIPLE-UNITS COMPOSITIONS OF NON-STEROID ANTI-INFLAMMATORY DRUG SUBSTANCES (NSAIDs) | NYCOMED DANMARK A/S (DK) | 2000-07-12 | — | — | EP | disclosed |
| WO-2000015195-A1 | QUICK RELEASE PHARMACEUTICAL COMPOSITIONS OF DRUG SUBSTANCES | NYCOMED DANMARK A/S (DK) | 2000-03-23 | — | — | WO | disclosed |
| US-5900247-A | Mucoadhesive pharmaceutical composition for the controlled release of active principles | ADIR ET COMPAGNIE (FR) | 1999-05-04 | — | — | US | disclosed |
| WO-1999012524-A1 | MODIFIED RELEASE MULTIPLE-UNITS COMPOSITIONS OF NON-STEROID ANTI-INFLAMMATORY DRUG SUBSTANCES (NSAIDs) | NYCOMED DANMARK A/S (DK) | 1999-03-18 | — | — | WO | disclosed |
| US-5672356-A | Bioadhesive pharmaceutical composition for the controlled release of active principles | ADIR ET COMPAGNIE (FR) | 1997-09-30 | — | — | US | disclosed |
| CN-1159950-A | Bioadhesive pharmaceutical composition for controlled release of active principles | ADIR (FR) | 1997-09-24 | — | — | CN | disclosed |